Skip to main content
Premium Trial:

Request an Annual Quote

Biofortuna to Further Commercialize Genotyping Assays With £1.6M Financing

NEW YORK (GenomeWeb) – Biofortuna today announced it has raised £1.6 million ($2.1 million) to support taking its genotyping assays into clinical trials and commercialization.

Investors in the new funding round included current investor venture capital firm Foresight and members of Biofortuna's senior management team. The company said that the funds will be used to take its ReadyPlex rapid blood group genotyping assays further toward commercialization, and allow Biofortuna to invest in additional resources in its contract manufacturing infrastructure.

ReadyPlex is based on PCR technology for the genomic analysis of blood groups, platelet antigens, neutrophil antigens, and coagulation polymorphisms. Biofortuna said that in addition to launching ReadyPlex products, it will invest in its freeze-drying production, and dispensing and packaging capabilities.

In January, the UK firm announced a new investment into its IVD service portfolio, allowing it to greater focus on immunoassay design, development, and manufacturing. The company also raised £1.5 million in early 2015.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.